Navigation Links
Vical to Present at Investor Conferences
Date:10/30/2007

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that its presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference will be webcast live on November 5 at 12:40 p.m. Eastern Time. Vical's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships. The webcast will be available live and archived for 90 days through the events page at http://www.vical.com.

The company's presentations at the BIOCOM Investor Conference (San Diego, October 31 - November 2) and at the Lazard Capital Markets Annual Life Sciences Conference (New York, November 27 - 28) will not be webcast.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contacts: Investors: Media:

Alan R. Engbring Susan Neath

Vical Incorporated Porter Novelli Life Sciences

(858) 646-1127 (619) 849-6007

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... JULABO USA is inviting visitors to ... website has been designed to provide the best user-friendly experience coupled with intuitive ... product information, read educational industry content as well as share information across all ...
(Date:12/7/2016)... Hole, Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew up ... Richard Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in the ... shore, where the turtle became a minor sensation because no one could remember ever seeing ...
(Date:12/6/2016)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... fiscal year ended September 30, 2016. ... , , SQI ... company that develops and commercializes proprietary technologies and products for advanced ... revenues of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
Breaking Biology Technology:
(Date:12/7/2016)... TEL AVIV, Israel , December 7, 2016 ... year with the expansion of its patent portfolio, which grew to over ... , , ... led by its recently filed patent entitled " System, Device, ... which covers technology that enables device makers to forego costly hardware components ...
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
Breaking Biology News(10 mins):